Curiouser and curiouser!
Back story here and here.
Now Forbes has learned that the lead investigator charged with conducting the ENHANCE study, John J. P. Kastelein of the University of Amsterdam, was not even present when the companies made the controversial decision to change its goals, an unusual circumstance in such situations.
It's "shocking" that Kastelein would not be party to discussion of the ENHANCE trial, says Harlan Krumholz, a cardiologist at Yale University. "There should be a scientific committee that's independent running a study. He should be taking a leadership role."
Much much more at Forbes
No comments:
Post a Comment